Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D001923:Brain Chemistry / Q000187:drug effects; D002415:Cats; D003863:Depression / Q000188:drug therapy; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004285:Dogs; D004298:Dopamine / Q000032:analysis; D004347:Drug Interactions; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D051379:Mice; D009069:Movement Disorders / Q000139:chemically induced; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011817:Rabbits; D051381:Rats; D009435:Synaptic Transmission / Q000187:drug effects
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D004298:Dopamine